BERLIN (GenomeWeb) – Laboratories at 11 institutions in Europe, Canada, and Japan have tested Thermo Fisher Scientific's Oncomine Lung cfDNA assay and found that it can detect low-level mutations in circulating free DNA control samples with high sensitivity and specificity.

Yesterday at the Association for Molecular Pathology AMP Global Congress in Berlin, Claudia Vollbrecht of the Institute of Pathology at Charité University Medicine Berlin presented the results of the study, which was conducted by the OncoNetwork Consortium, a network of researchers organized by Thermo.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Jul
24
Sponsored by
Qiagen

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Aug
09

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Aug
15
Sponsored by
Swift Biosciences

This webinar will discuss the Cancer Avatar Project at the California Pacific Medical Center Research Institute (CPMCRI) and the efforts to overcome complexity of tumor profiling using the Accel-Amplicon sequencing workflow from Swift Biosciences.